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Transforming growth factor beta I and sodium butyrate
differentially modulate urokinase plasminogen activator
and plasminogen activator inhibitor-I in human breast
normal and cancer cells
X Dong-Le Bourhis, V Lambrecht and B Boilly
Unite Dynamique des Cellules Embryonnaires et Cancereuses, Centre de Biologie Cellulaire, Universite des Sciences etTechnologies de Lille, 59655
Villeneuve d'Ascq Cedex, France
Summary The effects oftransforming growth factor beta 1 (TGF-i1) and sodium butyrate on cell proliferation and the urokinase plasminogen
activator (uPA) system were examined in normal human breast epithelial cells (HBECs) and in a breast cancer cell line, MDA-MB-231. In
HBECs, TGF-31 inhibited cell proliferation and uPA activity, while it augmented plasminogen activator inhibitor-1 (PAI-1) antigen level.
Sodium butyrate inhibited both cell proliferation and uPA activity but did not affect the level of PAI-1. In MDA-MB-231, TGF-31 had no effect
on cell proliferation but increased uPA activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but
had no effect on PAI-1 level. Moreover, in the presence of plasminogen, cell detachment could be modulated by the level of cell-associated
uPA. Our results indicate (1) thatthe effects ofTGF-13l on cell growth can be dissociated from its effects on the uPANPAI system; (2) that, while
TGF-,B1 is a potent inhibitor of cell proliferation and uPA activity in normal cells, it may promote invasion and metastasis of tumour cells by
increasing uPA activity and PAI-1 levels; and (3) that sodium butyrate offers a potential approach to preventing tumour development by
inhibiting both cell proliferation and invasion.
Keywords: urokinase plasminogen activator; plasminogen activator inhibitor-1; transforming growth factor beta 1; sodium butyrate; breast
epithelial cells; tumour invasion
Urokinase plasminogen activator (uPA) is a multi-domain serine
protease that is able to convert the inactive proenzyme plas-
minogen to plasmin. The plasmin activates prometalloproteinases
involved in degradation ofcollagen, laminin, fibronectin and other
matrix extracellularcomponents. This protease cascade is believed
to be involved in a variety ofphysiological as well as pathological
processes, including wound healing, tissue remodelling and cancer
invasion. Recent studies have shown that uPA is highly expressed
during tubular morphogenesis and involution of mammary gland
(Delannoy-Courdent et al, 1996; Lund et al, 1996). uPA-specific
antibodies attenuate the metastatic capacity of squamous cell
carcinoma to the lungs and lymph nodes (Ossowski et al, 1991).
Overexpression of uPA increases the metastatic rates of both
melanoma and prostate cancer (Yu et al, 1991; Achbarou et al,
1994). The enzymatic activity ofuPA is regulated by two specific
inhibitors, PAI-l and -2 (Andreasen et al, 1990) and by a specific
cell-surface receptor (uPA-R) (Blasi, 1993). uPA-R binds both
active uPA and its inactive proenzyme form, pro-uPA, with high
affinity. Pro-uPA can be activated to uPA by plasmin while bound
to uPA-R, and receptor-bound uPA in turn activates plasminogen.
Concomitant binding of plasminogen and pro-uPA to the cell
surface accelerates plasminogen activation, making the cell
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surface the preferential site for the urokinase pathway of plas-
minogen activation (Ellis et al, 1991). When uPA complexes with
PAI-i on the cell surface, it is internalized and degraded in a
process mediated by uPA-R (Blasi, 1993). Recently, it was
reported that tumour-associated uPA and PAI-I are strong and
independent negative prognostic factors for breast cancer patients
(Bouchet et al, 1994).
In vitro, uPA and PAls are regulated by a variety of hormones
and growth factors. TGF-j1 has been shown to be a major
regulator of the uPA/PAI-1 system in different cell types, such as
keratinocytes, fibroblasts and prostatic and lung carcinoma cells
(Laiho et al, 1986; Keski-Oja et al, 1988a and b; Desruisseau et al,
1996). In keratinocytes and prostate and lung tumour cells, TGF-
P1 increases the proteolytic activity of uPA and the synthesis of
PAI-1. More recently, it has been reported that in the human breast
cancer cell line MDA-MB-231, TGF-,B1 increases cell-associated
uPA protein and cell-secreted PAI-I levels (Arnoletti et al, 1995).
Another molecule, sodium butyrate, has also been investigated for
its anti-tumour activity. Sodium butyrate is a naturally occurring
four-carbon fatty acid, which appears to be a potent differentiating
agent for a wide range of neoplastic cells in vitro (Prasad, 1980).
In the human colon carcinoma cell line LIM 2405, sodium
butyrate stimulates the synthesis of PAI-I but inhibits both uPA
and uPA-R, indicating that sodium butyrate alters the balance of
uPA/PAI in a manner that favours net decreased plasminogen
activator activity (Reeder et al, 1993).
We have compared the responses to TGF-P1 and sodium
butyrate of normal human mammary epithelial cells with the
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responses of a malignant human mammary epithelial cell line in
terms ofcell proliferation, ofuPA activity and ofthe level ofPAI-1.
We have also examined the functional consequences of cell-
associated uPA levels by testing for uPA-dependent plasmin-
mediated cell detachment in vitro.
MATERIALS AND METHODS
Materials
The plasmin-specific chromogenic substrate H-D-Valyl-L-Leucyl-
Lysine-p-nitroanilide dihydrochloride (S-2251), plasmin-free plas-
minogen, TGF-,B1 and sodium butyrate were obtained from Sigma
(MO, USA). The anti-catalytic antibody against uPA and Imubind
Tissue PAI-I ELISA kit were purchased from American
Diagnostica (CT, USA). Materials for cell culture were from
Eurobio (France), except where otherwise indicated.
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Figure 1 Effect ofTGF-41 and sodium butyrate on cell proliferation. Cells
were seeded in 24-well plates and then treated with 2 ng mi-' TGF-jl or
1 mm sodium butyrate (NaB) in serum-free medium for 24 h as described in
Materials and methods. Cell proliferation was determined by measuring the
incorporation of [3H]thymidine. Results represent mean values ± s.d. of three
experiments and triplicate determination. *P< 0.01. A, HBECs; B, MDA-MB-
231 cells
Cell culture
Humanbreastcancercell line MDA-MB-231 (ATCC: HTB 26) was
cultured in Eagle's minimal essential medium (EMEM) supple-
mented with 10% fetal calf serum (FCS), penicillin (100 IU ml-'),
streptomycin (100 jg ml)-' gentamycin (40gg ml-'), L-glutamine
(2 mM), 1% non-essential amino acids and insulin (5 gg ml-';
Organon, France). Normal human breast epithelial cells (HBECs)
were obtained from mammary reduction (generous gift from Dr
Pellerin, Plastic Surgery, University of Medicine of Lille, France)
as previously described (Berthon et al, 1992) and cultured in
Dulbecco's Modified Eagle Medium (DMEM) F12 (1/1) (Sigma)
containing 5% FCS, 10 ,ug ml-' insulin, 5 x 10 M cortisol (Sigma),
100 ng ml-1 cholera toxin (Sigma) and 2 ng ml-' epidermal growth
factor (EGF) (Sigma).
[3H]Thymidine incorporation
Cells were seeded in 24-well plates (Coming Costar Corporation,
MA, USA). After 2 days, cells were washed with phosphate-
buffered saline (PBS) and treated withTGF-,B1 and sodium butyrate
for24 hin serum-free medium. Fourhours before the endofculture,
cells were incubated with 2 ,uCi ml-' [3H]thymidine (ICN, specific
activity 2 Ci mmol-1). Cells were then washed with 10% of
trichloroacetic acid (4°C), followed by four washes with water and
solubilized with 0.5 M sodium hydroxide; the radioactivity was
measured with aliquid scintillation counter (LKB Wallac).
Assays of uPA activity and PAI-1 level
Cells were seeded in 35-mm dishes (Greiner Labortechnik,
Germany) and 48 h later washed twice with PBS and then treated
with TGF-P1 and/or sodium butyrate in serum-free EMEM
without phenol red. After 24 h, the culture medium was collected
and centrifuged at 13 000 r.p.m. to remove cell debris. The cell
monolayers were extracted with 100 mM Tris-HCl pH 7.6/2 mm
EDTA/0.4% Triton X-100 (v/v) at 4°C for 15 min and scraped
with a rubber policeman. Cell extracts were then centrifuged at
13 000 r.p.m. to remove cell debris. All samples were stored at
-20°C until use. In parallel, cells treated in the same condition in
different dishes were harvested and counted using a haemocy-
tometer. uPA activity was determined by using the plasmin-
specific chromogenic substrate S-2251 as described previously
(Reinartz et al, 1993). Briefly, 50 ,ul of mammary cell extracts or
culture supematant was incubated with 50gl of S-2251 (1.5 mM)
and 50gl of plasminogen (60jig ml-') at 37°C in flat-bottomed
microtitre plates. The release ofparanitroaniline from S-2251 was
determined in each well by measuring the absorbance at 405 nm
using a microplate reader (Dynatech MR 700). Controls including
buffer alone and extracts with plasminogen were performed in
parallel wells. PAI-I levels were measured using an ELISA kit
according to the manufacturer's instructions.
Detachment of cultured cells
Cells were grown to preconfluence on 24-well plates (Coming) and
then treated withTGF-[B1 or sodiumbutyrate in serum-free medium
for 24 h. Cells were then washed twice in Ca2+- and Mg2+-free PBS
andincubated inthe presence orabsenceof0.4 IUml-' plasminogen
at37°C. Theplasminogen treatment was also performed in thepres-
ence of aprotinin (100 IU ml-') or anti-catalytic antibody against
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Figure 2 Effect of TGF-f1 and sodium butyrate on uPA activity. Cells were seeded in 35-mm dishes and then treated with 2 ng ml-1 TGF-31 or 1 mm sodium
butyrate in serum-free medium for 24 h. The cell-associated (A, C) and secreted (B, D) uPA activities were measured by an indirect chromogenic substrate
assay as described in Materials and methods. The data are given as optical density (OD)/cell number and represent mean values ± s.d. of three experiments
and triplicate determinations. A and B, HBECs; C and D, MDA-MB-231 cells
uPA (10 gg ml'). After30 min to 1 h ofincubation, cell monolayers
were washed twice with serum-free medium to eliminate reagents
and detached cells. Attached cells were analysed microscopically
and microphotographed (Olympus IMT-2). For the quantification of
attached cells, cells were washed twice with PBS, trypsinized and
counted using ahaemocytometer.
Statistical analysis
Statistical significance between control and treatment groups was
calculated using the Student t-test and the computer programme
Statview.
RESULTS
Effect of TGF-i1 and sodium butyrate on cell
proliferation
Different concentrations ofTGF-P1 (0.05-5 ng ml-1) and sodium
butyrate (0.1-4 mM) were tested for their effect on cell prolifera-
tion. The optimal concentration of TGF-,1 and sodium butyrate
was determined to be 2 ng ml' and 1 mm respectively. For the rest
of the experiments, cells were therefore treated with 2 ng ml-'
TGF-P1 and 1 mm sodium butyrate for 24 h in serum-free medium.
At 2 ng ml', TGF-,1 inhibited significantly (P < 0.01) the incor-
poration of [3H]thymidine in HBECs (about 60% of control)
(Figure IA) but had no such effect on MDA-MB-231 cells (Figure
iB). However, sodium butyrate (1 mM) inhibited the incorporation
of [3H]thymidine in both HBECs and MDA-MB-231 cells with
similar efficiency (about 50% ofcontrol) (Figure IA and B).
Effects ofTGF-P and sodium butyrate on uPA activity
In HBECs, TGF-,1 decreased cell-associated uPA to about 35% of
the control value (Figure 2A) and secreted uPA to 10% of the
control value (Figure 2B). Sodium butyrate reduced the cell-asso-
ciated (Figure 2A) and secreted (Figure 2B) uPA activity by about
50%. uPA activity was inhibited to an even greater extent when
cells were treated with both sodium butyrate and TGF-1I (about
17% of control for cell-associated uPA and 5% for secreted uPA)
(Figure 2A and B). For MDA-MB-231 cells, TGF-P1 strongly
increased the uPA activity (about threefold for cell-associated uPA
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Figure 3 Effect ofTGF-,B1 and sodium butyrate on PAI-1 levels. Cells were seeded and treated with 2 ng ml-' TGF-,1l and 1 mm sodium butyrate as described
in Figure 2. The cell-associated (A, C) and secreted (B, D) PAI-1 levels were measured by ELISA. Results represent mean values ± s.d. of two experiments and
duplicate determination. *P< 0.01. A, and B, HBECs; C and D, MDA-MB-231 cells
and 11-fold for secreted uPA) (Figure 2C and D), while sodium
butyrate reduced both cell-associated and secreted uPA activity
(about 50% ofcontrols) (Figure 2C and D). When MDA-MB-231
cells were treated with sodium butyrate and TGF-P1 together,
sodium butyrate only partly inhibited the increase of uPA activity
induced by TGF- 1 (Figure 2C and D).
Effects of TGF-,B and sodium butyrate on PAI-1 levels
TGF-,I increased cell-associated PAI-I about five- to sixfold
(Figure 3A and C) and cell secreted PAI 110-fold (Figure 3B and
D) in both HBECs and MDA-MB-231 cells. Sodium butyrate had
no effect on the level ofPAI-I in either HBECs or MDA-MB-231
cells. However, when cells were treated with TGF-,B1 and sodium
butyrate together, the levels of PAI-i were higher than those of
cells treated withTGF-P1 alone (Figure 3).
Effect ofTGF-0 and sodium butyrate on cell
detachment
One hour after incubation with plasminogen, untreated HBECs
became rounded and detached from the culture plate (Figure 4,
panel B). In contrast, only a few TGF-pl-treated cells were
rounded after a 1-h incubation with plasminogen, and no cell
detachment was detectable (Figure 4, panel B). Sodium butyrate-
treated cells also became rounded after plasminogen incubation
and a few ofthem detached from the culture plate (Figure 4, panel
B). For the MDA-MB-231 cells, 30min after incubation with
plasminogen, no cell detachment was observed in either control or
sodium butyrate-treated cells, although the cells became slightly
more rounded (Figure 5, panel B). However, TGF-31-treated cells
became more rounded and were detached from the culture plate
after 30 min of incubation with plasminogen (Figure 5, panel B).
Moreover, simultaneous incubation ofcells with aprotinin (Figure
4, panel C; Figure 5, panel C) or a neutralizing antibody to uPA
(Figure 4, panel D; Figure 5, panel D) in the presence of plas-
minogen prevented cell detachment, indicating that cell detach-
ment in the presence of plasminogen was specific to plasmin
activated by uPA. Attached cells were also quantified after
different incubations (Figure 6). After 1 h ofincubation with plas-
minogen, only about 20% ofuntreated HBECs remained attached,
whereas about 70% of TGF-j1- and NaB-treated cells were
attached (Figure 6A). For the MDA-MB-231 cells, after a 30-min
incubation with plasminogen, almost all of the control and NaB-
treated cells remained attached, while only about 40% ofTGF-,B1-
treated cells were attached (Figure 6B). Simultaneous incubation
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Figure 4 Cell detachment assay of HBECs. Cells were seeded in 24-well plates and cultured with TGF-B1 and sodium butyrate (NaB) in serum-free medium
for 24 h. Cells were then washed and incubated in the absence (A) or presence of 0.4 IU ml-' plasminogen (B) for 1 h at 370C. The plasminogen incubation was
also performed in the presence of 100 IU ml-' aprotinin (C) or 10 igg ml-' anti-catalytic uPA antibody (D) for 1 h at 370C. Detached cells were eliminated by
washing two times with serum-free medium. Activation of added plasminogen was ensured by rounding and detachment of cells from culture plates.
Magnification x200
ofcells with aprotinin or neutralizing antibody to uPA in the pres-
ence ofplasminogen prevented cell detachment (Figure 6).
DISCUSSION
uPA is considered to be an indicator of poor prognosis in breast
cancer. Immunocytochemical analysis shows that uPA, PAI-1 and
uPA-R are expressed at a higher level in cancerous breast tissues
than in benign tissues (Jankun et al, 1993). However, in our study,
we have shown that normal breast epithelial cells (HBECs) possess
more uPA activity than the malignant breast cell line MDA-MB-
231, whereas the PAI-l levels were similar in both cell types. As
mammary epithelial cells possess both uPA and tPA, we have also
measured the uPA activity in the presence of amiloride, a specific
inhibitor ofuPA (Vassali and Belin, 1992), no conversion ofS2251
was detected in this condition, indicating that the proteolytic
activity measured in our conditions is due to the uPA activity (data
not shown). One explanation of ourobservations is that the HBECs
have a complete and intact adhesion system, as well as a well-
developed extracellularmatrix. Therefore, these cells mightrequire
more proteolytic activity to degrade the matrix for migration in the
basal cell culture condition. In contrast, tumoral cells show
frequent defects in cell-adhesion receptors, such as the integrins
(Gould et al, 1990; Jones et al, 1992) as well as extracellular
matrix, including thrombospondin and laminin (Gould et al, 1990;
Zabrenetzky et al, 1994). Consequently, tumourcells might require
less proteolytic activity for migration in the basal cell culture
condition. Another possibility is that the action of growth factors,
such as TGF-P, hepatocyte growth factor (HGF) and fibroblast
growth factor (FGF), requires the activation and/or release ofthese
factors from extracellular matrix, which may be degraded by uPA.
As normal cells produce more growth factor-binding extracellular
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Figure 5 Cell detachment assay of MDA-MB-231 cells. Cells were seeded in 24-well plates and cultured with TGF-,B1 and sodium butyrate (NaB) in serum-
free medium for 24 h. Cells were then washed and incubated in the absence (A) or presence of 0.4 IU ml-' plasminogen (B) for 30 min at 370C. The
plasminogen incubation was also performed in the presence of 100 IU ml-1 aprotinin (C) or 10 igg ml-1 anti-catalytic uPA antibody (D) for 30 min at 370C. Cells
were then processed as described for HBECs in Figure 4
matrix molecules, such as heparan sulphate proteoglycans than
tumoral cells (Delehedde et al, 1996; unpublished results), it is
possible that normal cells need more proteolytic activity to degrade
the growth factor binding extracellular matrix to maintain cell
growth, particularly in serum-free culture conditions.
We have shown that in the human breast cancer cell line MDA-
MB-231, TGF-,B1 strongly increased cell-associated and secreted
uPA activity. When a cell detachment assay was performed, TGF-
I1-treated cells became rounded and detached more rapidly than
untreated cells. Cell detachment could be prevented by adding a
neutralizing antibody against uPA or the serine protease inhibitor
aprotinin. These results indicate that TGF-,1 increased uPA
activity, which in turn activated plasmin, thus allowing the degra-
dation of extracellular matrix and cell detachment. In addition,
we have found that TGF-01 also increased the PAI-I level in
the MDA-MB-231 cells. These results agree with those of
Desruisseau et al (1996), in which TGF-,1 induced uPA mRNA
expression, secreted uPA activity and secreted PAI-1 levels in
prostatic cancercell lines. Additionally, Amoletti et al (1995) have
showed thatTGF-P1 enhances cell-associated uPA expression and
secreted PAI-I levels in the human breast cancer cell line MDA-
MB-23, consistent with ourresults; but the authors did not observe
any change in uPA level in conditioned medium, contrary to our
findings. However, as the authors measured uPA protein level
only, by ELISA, but not uPA activity, it is possible that the protein
level ofuPA would not correctly reflect its proteolytic activity as it
is regulated by other factors, such as PAI-1, PAI-2 and uPA-R
(Andreasen et al, 1990; Blassi et al, 1993). The simultaneous up-
regulation of uPA and PAI-I in the tumour cells should be
considered as being complementary: increased cell-associated
uPA induces pericellular protein degradation, favouring cell
detachment, while increased PAI-1 levels reduce indiscriminant
extracellular matrix degradation, which would deprive invasive
cells of the anchorage necessary for cell locomotion. Moreover,
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Figure 6 Quantification of attached cells after incubation with plasminogen.
Cells were seeded in 24-well plates and cultured with TGF-,B1 or sodium
butyrate in serum-free medium for 24 h. Cells were then processed as
described in Figures 4 and 5. Detached cells were eliminated by washing two
times with PBS, and attached cells were then trypsinized, harvested and
counted using a haemocytometer. Results represent mean values ± s.d. of
three experiments and triplicate determinations. *P< 0.01. A, HBECs;
B, MDA-MB-231 cells
Deng et al (1996) have recently reported that PAI-I promotes cell
detachment by interacting with vitronectin, independent of its
activity to function as a protease inhibitor. In our study, although
TGF-,B1 strongly increased uPA and PAI-I in MDA-MB-231 cells,
it did not inhibit cell proliferation. This is consistent with the work
of Keski-oja et al (1988a and b), which showed that the human
lung carcinoma cell line A549 is not growth inhibited by TGF-, 1,
but responds to TGF-,B1 treatment by changes in the expression of
matrix components andenhancedproteolytic activity. Additionally,
our observations agree with those of Geiser et al (1992) showing
that human carcinoma cell lines that are not growth inhibited by
TGF-01 are still capable of responding with increased levels of
fibronectin, type IV collagenase and PAI-1. The loss ofresponsive-
ness of tumour cells to the antiproliferative effect of TGF-P1
appears to be a frequent event in the progression of malignant
tumours (Markowitz and Roberts, 1996). Multiple changes are
required forthe cells to gain complete resistance toTGF-PI growth
inhibition (Fynan and Reiss, 1993). Recent work has demonstrated
that patients suffering from invasive prostatic cancer present a
higher plasma TGF-,B level (Ivanovic et al, 1995), suggesting a
role ofTGF- 1 in tumour invasion.
In contrast to MDA-MB-231 tumourcells, HBECs were growth
inhibited by TGF-01. Moreover, TGF-p1 decreased uPA activity
but augmented PAI-I antigen level in these cells. TGF-i1
prevented cell detachment of HBECs by inhibiting uPA activity.
These results agree with previous studies in fibroblast cells
demonstrating that TGF-i1 reduces expression of proteases, such
as collagenase and uPA, while increasing expression of protease
inhibitors, such as PAI-I and tissue inhibitor of metalloproteinase
(Laiho et al, 1986; Overall et al, 1991). However, Stampfer et al,
(1993) havereported thatTGF-P1 strongly induces the mRNA and
protein synthesis ofuPA and PAI-I in human mammary epithelial
cells, but they did not determine the uPA activity.
TGF-lI is synthesized as a biologically inactive form, which
can be converted into the active form by limited proteolysis.
Plasmin is one of the factors capable of activating the latent form
of TGF-i1. As TGF-PI is produced by both MDA-MB-231 cells
and HBECs (Valverius et al, 1989; Arrick et al, 1990), the
enhanced production of plasmin by TGF-P1 would provide a
positive feedback loop in the regulation of plasmin-mediated
proteolysis in the breast tumour cell line MDA-MB-231, whereas
the decreased production ofplasmin byTGF-P1 in HBECs would
provide a negative feedback in normal breast epithelium.
We have also found that sodium butyrate inhibited both cell
proliferation and uPA activity in both HBECs and MDA-MB-231
cells. This is consistent with the finding of Reeder et al (1993),
demonstrating that in the human colon carcinoma cell line LIM
2405, sodium butyrate regulates the balance of uPA/PAI-1 in a
manner that favours net decreased plasminogen activator activity.
Sodiumbutyrate has been reported to induce cell differentiation of
a wide range of tumour cells (Prasad, 1980). It thus may prevent
tumour development by inhibiting cell proliferation and invasion
as well as by inducing cell differentiation.
In conclusion, our results indicate that (1) while TGF-P1 was a
potent inhibitor for cell proliferation and uPA activity in normal
cells, it may promote invasion and metastasis of tumour cells by
increasing uPA activity and PAI-i levels; (2) sodium butyrate
treatment offers apromising approach to preventing tumour devel-
opment by inhibiting cell proliferation and invasion. However,
recent works have demonstrated that uPA, uPA-R and PAI-I influ-
ence cell adhesion in a process independent of uPA-mediated
proteolysis (Waltz and Chapman, 1994; Deng et al, 1996). The
possibility ofsuch influence on cell adhesion in ourmodel remains
unknown and further studies should be performed to understand
the mechanismby whichTGF-PI and otherinhibitory agents regu-
late cell adhesion/migration in the context ofthe uPA system.
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